Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

iwMyeloma 2015 | Immunotherapy for the treatment of multiple myeloma

David Avigan • 11 Apr 2015
iwMyeloma 2015
Multiple Myeloma Antibodies Checkpoint inhibitors

At the Myeloma 2015, Dr David Avigan (Beth Israel Deaconess Medical Center, Boston, MA) discusses the development of immune checkpoint inhibitors, including anti-PD-1 antibodies, for the treatment of multiple myeloma (MM). An emerging focus has been on combination therapies and enhancing the anti-MM immune response during treatment using vaccination approaches.

More from David Avigan

Impact of dendritic cell fusion vaccine on the microenvironment and outcomes in multiple myeloma
2:26
Impact of dendritic cell fusion vaccine on the microenvironment and outcomes in multiple myeloma
David Avigan • 26 Aug 2022
The role of vaccines in AML
1:26
The role of vaccines in AML
David Avigan • 26 Aug 2022
Immune dysregulation in myeloma and impact on disease progression
1:10
Immune dysregulation in myeloma and impact on disease progression
David Avigan • 26 Aug 2022
Vaccines and immunotherapy in hematological malignancies
3:31
Vaccines and immunotherapy in hematological malignancies
David Avigan • 8 Sep 2020

Related Videos

A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
David Avigan • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
David Avigan • 15 Dec 2025
Motixafortide + G-CSF HSC mobilization in pts with myeloma following quadruplet induction therapy
1:40
Motixafortide + G-CSF HSC mobilization in pts with myeloma following quadruplet induction therapy
David Avigan • 6 Dec 2025
WGS of cfDNA for assessment of MRD in high-risk smoldering multiple myeloma
2:13
WGS of cfDNA for assessment of MRD in high-risk smoldering multiple myeloma
David Avigan • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals